CGRP Antibody Therapy: A New Frontier in Migraine Treatment
Justin DeLange, DO, FAHS
Dr. DeLange discloses he is a consultant for Amgen
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Arizona Osteopathic Medical Association (AOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
GRIEVANCE POLICY: The AOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to AOMA Executive Director Josephine Zammuto, by calling the AOMA Office at 602-266-6699 or by mail to AOMA, 1951 W. Camelback Rd., Suite 105, Phoenix, AZ 85015, or by email to email@example.com
|CGRP Antibody Therapy: A New Frontier in Migraine Treatment - Handout (95 KB)||31 Pages||Available after Purchase|
Justin Delange, DO is a board certified neurologist. His practice in Flagstaff, Arizona focuses on general neurology with subspecialty expertise in headache and management of facial pain. He is proficient in peripheral nerve block and Botox injections for headache treatment. His clinical interests involve treating intractable headaches such as chronic migraine; biobehavioral approaches to treatment and advocacy for headaches. Dr. DeLange completed an internal medicine internship and neurology residency at the University of Texas Health Science Center at Houston, where he also serviced as neurology chief resident. He completed a headache medicine fellowship at the Mayo Clinic Department of Neurology, Rochester, Minnesota. He is certified in the subspecialty of Headache Medicine by the United Council for Neurologic Subspecialties. Dr. DeLange is a member of the Arizona Osteopathic Medical Association, Gold Humanism Honor Society, the American Headache Society, and the American Academy of Neurology.
Dr. DeLange has no disclosures.
Please wait ...